Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
Completed · Phase 1
Conditions studied: Healthy Volunteer
In brief
This is a Phase 1, open-label, 2-period fixed sequence design to evaluate the interaction of AZD9291 with omeprazole in approximately 50 healthy, adult male volunteers. Volunteers will receive Treatment A (AZD9291 and omeprazole) in Period 1 and Treatment B (AZD9291 only) in Period 2. The dose of AZD9291 in Period 1 and the dose of AZD9291 in Period 2 will be separated by a washout of at least 21 days (the washout will not be more than 5 weeks). The study will be performed at up to 2 sites in the USA and will assess the effect of omeprazole (proton pump inhibitor) on AZD9291 exposure
Key facts
- Study ID
- NCT02224053
- Run by
- AstraZeneca
- People needed
- 136
- Starts
- 2014-09-01
- Expected to finish
- 2015-01-01
- Last updated by the study team
- 2016-06-24
Who can join
Age: 18 and older, up to 55. Sex: male. Healthy volunteers: accepted.
Where it is running
- Research Site — Overland Park, Kansas, United States
- Research Site — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.